Replimune Group (NASDAQ:REPL) Stock Price Up 6.7% - Should You Buy?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) traded up 6.7% on Monday . The company traded as high as $8.16 and last traded at $8.53. 41,152 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 863,411 shares. The stock had previously closed at $8.00.

Analyst Ratings Changes

REPL has been the subject of several analyst reports. BMO Capital Markets boosted their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their price objective on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $19.43.

Replimune Group Price Performance

The firm has a market capitalization of $696.99 million, a P/E ratio of -2.95 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The business has a 50 day simple moving average of $10.24 and a two-hundred day simple moving average of $11.66.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, sell-side analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Institutional Trading of Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Boxer Capital Management LLC purchased a new stake in Replimune Group in the fourth quarter worth approximately $21,754,000. Tang Capital Management LLC lifted its holdings in Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after purchasing an additional 1,500,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Replimune Group by 11.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after buying an additional 1,083,633 shares during the period. MPM Bioimpact LLC purchased a new stake in shares of Replimune Group during the fourth quarter worth about $11,504,000. Finally, RTW Investments LP lifted its holdings in shares of Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock worth $25,007,000 after buying an additional 931,223 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.